Entegrion Announces Appointment of W. Brian Gibler, M.D. to its Board of Directors

Share Article

Accomplished healthcare professional to help advise on advanced development and launching of the Company’s first commercial products

We are extremely pleased to have such an accomplished healthcare professional join our Board during this period of advanced development, and the launching of the Company’s first commercial products.

North Carolina-based life sciences company, Entegrion, Inc., announces the appointment of W. Brian Gibler, M.D., Professor, Emergency Medicine, University of Cincinnati, to the Company’s Board of Directors.

A graduate of Brown University and Vanderbilt University Medical School, Dr. Gibler received his Emergency Medicine Residency Training at the University of Cincinnati Medical Center. Dr. Gibler’s career in healthcare leadership has included serving as the Chairman of the Department of Emergency Medicine at the University of Cincinnati College of Medicine and Medical Director of Emergency Services at the University of Cincinnati Medical Center for 15 years, followed by his appointment as President and Chief Executive Officer of the University of Cincinnati Medical Center in 2010. He currently serves as Professor of Emergency Medicine at the University of Cincinnati College of Medicine. Dr. Gibler, with over three decades of research, education, and clinical experience, is a recognized international authority and leading figure in the field of Emergency Medicine and Emergency Cardiac Care, with his research focus on the early diagnosis and treatment of acute coronary syndromes. He has been awarded the distinction of Fellow both in the American College of Emergency Physicians and the American College of Cardiology.

Actively engaged in research, in 1989 Dr. Gibler founded the Emergency Medicine Cardiac Research and Education Group (EMCREG)-International to conduct multi-center clinical research on serum markers for the early diagnosis of acute myocardial infarction and subsequently evaluate many diagnostic and treatment modalities for acute coronary syndromes. Since that time EMCREG-International has evolved into an international research and education network involving more than thirty leading academic research institutions across the world.    

Entegrion’s Executive Chairman John B. Mowell said, “We are extremely pleased to have such an accomplished healthcare professional join our Board during this period of advanced development, and the launching of the Company’s first commercial products.”

“Entegrion is developing a unique combination of therapeutic products for resuscitation and control of hemorrhage, along with a state-of-the-art, advanced diagnostic platform for determining a patient’s coagulation status at the bedside (point-of-care). These products will positively impact the way physicians evaluate and treat critically ill and injured patients in the emergency department, critical care units, and operating room,” said Gibler.

Mowell added, “Brian is a recognized leader in healthcare and clearly understands the dynamics of Entegrion’s business. His appointment as a director will contribute importantly to the Company’s development going forward.”

About Entegrion
Entegrion, Inc. is a life sciences product development company that is focused on improving the safety and availability of the world’s blood supply. Based in North Carolina’s Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion’s advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tamara Baker
Entegrion
+1 (919) 951-9282
Email >
Visit website